BioMedNewsBreaks — OneMedNet Corporation (NASDAQ: ONMD) Moves to Solidify Cash Position, Accelerate Growth

OneMedNet (NASDAQ: ONMD) is the leading curator of regulatory-grade Real World Data (“iRWD(TM)”) through its proven OneMedNet iRWD(TM) solution. The company recently announced that it has entered into a definitive securities purchase agreement, dated as of March 28, 2024, with an institutional investor providing up to $4.54 million in funding through a private placement for the issuance of senior convertible notes. OneMedNet intends to use the net proceeds from the offering for working capital purposes. “This securities purchase agreement demonstrates confidence in our comprehensive iRWD(TM) platform, marking an important milestone for OneMedNet as we have the investment needed to expedite our growth, enhance our network, and propel the development of our AI-driven solutions. Our platform is designed to meet the clinical requirements necessary across various domains, including but not limited to rare diseases, oncology and cardiology. We are committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of our strategy to enhance patient outcomes and pave the next wave of healthcare innovation,” said Aaron Green, president and CEO of OneMedNet.

To view the full press release, visit https://ibn.fm/dkfnD

About OneMedNet Corporation

Founded in 2009, OneMedNet provides innovative solutions that unlock the significant value contained within the clinical data repositories of healthcare providers. OneMedNet’s robust iRWD(TM) platform provides secure, comprehensive management of diverse clinical data types, including electronic health records (“HER”), laboratory results and medical imaging data. Employing its proven OneMedNet iRWD(TM) platform, OneMedNet securely de-identifies, searches and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to healthcare providers. By leveraging this extensive federated provider network, together with industry leading technology and in-house clinical expertise, OneMedNet successfully meets the most rigorous RWD Life Science requirements. Its commitment to leveraging real-world data translates into healthcare innovations, setting new standards in patient care and advancing the future of medicine. For more information, please visit www.OneMedNet.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present Sapu003 Data at 2025 San Antonio Breast Cancer Symposium

Oncotelic Therapeutics (OTCQB: OTLC) a biopharmaceutical company advancing transformative cancer therapies through its PDAOAI platform…

13 minutes ago

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Schedules Third Quarter 2025 Conference Call for Nov. 13 

HeartBeam (NASDAQ: BEAT), a medical technology company transforming cardiac care through personalized insights, will hold…

22 hours ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Advances 

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Nanomedicine Innovations…

24 hours ago

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Granted 180-Day Nasdaq Extension to Regain Minimum Bid Price Compliance

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology…

2 days ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Receives FDA Meeting Feedback Advancing AVERSA(TM) Fentanyl Toward 505(b)(2) NDA Submission 

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, today announced it has received…

3 days ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Innovations in Oncology

Oncotelic Therapeutics (OTCQB: OTLC) today announced its inclusion in an editorial published by NetworkNewsWire (“NNW”),…

3 days ago